PDL BioPharma Announces Launch of an Authorized Generic of Tekturna® (aliskiren) in Partnership with Prasco Laboratories
Noden will continue to manufacture and commercialize prescription aliskiren products under the Tekturna and Tekturna HCT® (aliskiren and hydrochlorothiazide) brands in
"We believe being first-to-market with a generic version of aliskiren provides Noden with a distinct competitive advantage, especially given the market and brand recognition for Tekturna that the Noden team established with its promotional activities over the past two years," said
Total Noden sales of the Tekturna Products in
Tekturna (aliskiren) is indicated for the treatment of hypertension in adults and children 6 years of age and older. A direct renin inhibitor, Tekturna has a unique mechanism of action in that it lowers blood pressure by blocking the enzyme renin. The prescribing information for Tekturna includes a boxed warning for fetal toxicity, a contraindication against the use of aliskiren with ARBs (angiotensin-receptor blockers) or ACEIs (angiotensin converting enzyme inhibitors) in patients with diabetes, and a warning to avoid the use of aliskiren with ARBs or ACEIs in patients with moderate to severe renal impairment.
PDL BioPharma seeks to provide a significant return for its stockholders through the acquisition, growth and potential monetization of a portfolio of actively managed pharmaceutical assets. PDL is pursuing the acquisition of pharmaceutical products and companies that have the potential of generating significant shareholder value. PDL is focused on commercial stage assets with multiple year revenue growth potential as well as late clinical stage pharmaceutical products.
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Important factors that could impair the value of the Company's assets and business are disclosed in the risk factors contained in the Company's Annual Report on Form 10-K, filed with the
View original content to download multimedia:http://www.prnewswire.com/news-releases/pdl-biopharma-announces-launch-of-an-authorized-generic-of-tekturna-aliskiren-in-partnership-with-prasco-laboratories-300806056.html
PDL BioPharma, Inc., Peter Garcia, CFO, (775) 832-8500, Peter.firstname.lastname@example.org; LHA Investor Relations, Jody Cain, SVP, (310) 691-7100, email@example.com